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Transcatheter aortic valve implantation 
(TAVI) is a widely accepted treatment method 
in patients with severe AS at intermediate and 
high surgical risk.2,3 This minimally invasive 
technique does not require thoracotomy or use 
of cardiopulmonary bypass, reduces the overall 
risk of valve implantation, shortens hospitaliza‑
tion time, and is less limited by patient frailty. 
The procedure was initially intended for inoper‑
able individuals and has revolutionized the care 
INTRODUCTION In developed countries, aor‑
tic valve stenosis is the most frequent acquired 
valvular heart disease requiring intervention‑
al treatment and, due to population aging, its 
prevalence is increasing. The frequency of aor‑
tic stenosis (AS) is approximately 4% to 5% in 
patients aged over 65 years and increases with 
age.1 Aortic valve stenosis is nowadays the most 
common indication for valve surgery and trans‑





















BACKGROUND Rapid ventricular pacing is used during balloon aortic valvuloplasty, balloon ‑expandable 
transcatheter aortic valve implantation (TAVI), and for postdilatation. Right ventricular (RV) lead pacing 
has been regarded as a gold standard. Direct left ventricular (LV) wire pacing has recently been considered 
safe and effective in TAVI interventions.
AIMS This study aimed to analyze procedural outcomes of direct LV pacing compared with RV stimulation 
in unselected patients undergoing TAVI.
METHODS Direct LV wire pacing was provided via available preshaped guidewires and used only when 
no predictors of atrioventricular block were present. The primary study objective was the assessment of 
the efficacy of direct LV wire pacing. The secondary objectives included the evaluation of procedure 
duration and safety in comparison with the conventional method. A combined endpoint (major adverse 
cardiovascular event) was defined as the occurrence of death, stroke, venous puncture–related complications, 
and cardiac tamponade.
RESULTS In 2017 and 2018, 143 patients underwent transfemoral TAVI. Of these, 114 (79.7%) had self‑
‑expandable valves implanted. Direct LV wire pacing was the dominant method of pacing (82 patients 
[57.3%]), and its efficacy reached 97.6%. The median (interquartile range) procedure time was shorter 
in the direct LV wire pacing group (80 [70–90] min vs 85 [70–95] min; P = 0.02). Major adverse cardiovascular 
events were more frequent in the RV lead pacing group (11.5% vs 4.9%), but no statistical significance 
was achieved (P = 0.13).
CONCLUSIONS Direct LV wire pacing during TAVI is a simple, reproducible, and safe technique, which 
provides reliable, sustained stimulation with a low complication rate and potential reduction of 
procedural time.
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METHODS A retrospective, observational study 
was conducted in a single center performing 
more than 100 TAVI procedures annually. All 
consecutive patients with severe AS who under‑
went transfemoral TAVI were included.
Patients were divided into 2 groups: the di‑
rect LV wire pacing group and the RV lead pac‑
ing group. Direct LV wire pacing was used when 
no predictors of atrioventricular block (AVB) 
(first ‑degree AVB, Mobitz I block, right bundle 
branch block, or left anterior hemiblock) were 
present. Moreover, the final choice of the pacing 
method was left at the operator’s discretion to 
obtain safe and effective stimulation.
The primary objective of the study was to as‑
sess the efficacy of direct LV wire pacing during 
TAVI procedures. Secondary objectives included 
the evaluation of procedure duration and safe‑
ty in comparison with the conventional meth‑
od. We defined a combined endpoint of major 
adverse cardiovascular events including death, 
stroke, venous puncture–related complications, 
and cardiac tamponade.
The study was approved by the local ethics 
committee and conducted in accordance with 
the 1964 Declaration of Helsinki with its lat‑
er amendments.
Procedural technique In the RV lead pacing 
group, a femoral vein puncture was performed 
and an intravenous 6‑French sheath was intro‑
duced. Stimulation was provided with a tem‑
porary transvenous pacing electrode (Hagmed, 
Rawa Mazowiecka, Poland) with a standard 
(without a balloon), flexible, curved distal tip. 
Pacing was performed with an output of 10 mA 
and a frequency of 140 bpm to 180 bpm. Femo‑
ral vein access hemostasis was routinely achieved 
with the 6‑French Angio ‑Seal (Terumo Interven‑
tional Systems, Somerset, New Jersey, United 
States) vascular closure device.
No routine femoral vein puncture was per‑
formed in the direct LV wire pacing group. 
of patients with AS. Furthermore, indications 
for TAVI are constantly being extended towards 
patients at lower surgical risk.4,5
Although TAVI has already become a well‑
‑established technique with many improvements 
reducing procedural risk (subsequent generations 
of valves, downsized diameter of delivery sheaths, 
complete percutaneous approach, conscious se‑
dation), the use of rapid pacing remained un‑
changed. Rapid ventricular pacing is used dur‑
ing balloon aortic valvuloplasty (BAV), balloon‑
‑expandable valve implantation, and postdilata‑
tion to ensure transient cardiac standstill. Tradi‑
tionally, right ventricular (RV) lead pacing is used; 
however, direct left ventricular (LV) wire pac‑
ing via a routinely used guidewire is possible.3-10
Right ventricular lead pacing requires addition‑
al venous access and a pacing catheter, which may 
be the reason for higher complication risk in frail 
patients. It extends procedural time and radiation 
exposure. Left ventricular wire pacing may po‑
tentially shorten the TAVI procedure, reduce its 
complexity, and enhance safety. This approach is 
considered safe and effective and was previous‑
ly described in BAV and TAVI interventions.6-11
Our study aimed to assess the safety and effi‑
cacy of this new technique as well as procedural 
outcomes in a population of unselected patients 
undergoing TAVI.
WHAT’S NEW?
In this article, we report our center’s experience in using the new direct left 
ventricular stimulation technique in patients undergoing transcatheter aortic 
valve implantation (TAVI) procedures. This is the first study to compare the use 
of direct left ventricular wire pacing and the conventional method (right 
ventricular lead pacing) in the population of unselected patients undergoing 
transfemoral TAVI procedures in a single Polish center. Our study confirmed 
the suitability of left ventricular guidewire pacing in a broad range of all ‑comers 
with the use of both balloon‑ and self ‑expandable valves to reduce the overall 
risk of valve implantation. Risk optimization in TAVI by simplifying the procedure 
is a new and up ‑to ‑date issue.
A B
FIGURE 1 Pacing pins. The cathode is attached to the tip of the guidewire (A), and the anode to a needle inserted into the subcutaneous tissue of the groin (B).
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a connection pin on the tip of the wire, and 
the anode was connected to a needle insert‑
ed into the subcutaneous tissue of the groin 
(FIGURE 1). Insulation was ensured by a balloon 
or TAVI catheter. To achieve effective stimu‑
lation, pacing was performed with a maximal 
output of 20 mA and a frequency of 140 bpm to 
Left ventricular wire pacing was provided 
via commercially available preshaped guide‑
wires: Safari (Boston Scientific, Marlborough, 
Massachusetts, United States) and Confida 
(Medtronic, Minneapolis, Minnesota, Unit‑
ed States). The cathode of an external pace‑
maker was placed using an alligator clamp or 
TABLE 1 Baseline characteristics of the study patients
Characteristic All study patients (n = 143) Direct LV wire pacing (n = 82) RV lead pacing (n = 61) P value
Age, y, median (IQR) 81 (78–84) 81 (77–84) 81 (78–85) 0.68
Female sex 88 (61.5) 47 (57.3) 41 (67.2) 0.74
BMI, kg/m2, median (IQR) 28.1 (25–31.2) 28.4 (25.1–31.3) 28.1 (24.7–31.2) 0.73
Patient history
COPD 24 (16.8) 16 (19.5) 8 (13.1) 0.24
Stroke / TIA 12 (8.4) 5 (6.1) 7 (11.5) 0.47
PAD 16 (11.2) 9 (11) 7 (11.5) 0.83
Renal failurea 8 (5.6) 4 (4.9) 4 (6.6) 0.73
PCI 48 (33.6) 26 (31.7) 22 (36.1) 0.86
CABG 20 (14) 12 (14.6) 8 (13.1) 0.65
Frailtyb 32 (22.4) 18 (22) 14 (23) 0.18
PH 31 (21.7) 16 (19.5) 15 (24.6) 0.69
Chest irradiation 6 (4.1) 4 (4.9) 2 (3.3) 0.69
Porcelain aorta 19 (13.3) 12 (14.6) 7 (11.5) 0.61
NYHA class
I 5 (3.7) 4 (4.9) 1 (1.9) 0.2
II 59 (43.4) 37 (45.1) 22 (40.7)
III 60 (44.1) 37 (45.1) 23 (42.6)
IV 12 (8.8) 4 (4.9) 8 (14.8)
Risk scores
EuroSCORE II, %, median (IQR) 3.2 (1.9–5.4) 3 (1.8–4.9) 3.2 (1.9–5.7) 0.62
STS, %, median (IQR) 3.7 (2.7–5.8) 3.6 (2.5–5.1) 3.8 (2.8–6.8) 0.17
Echocardiography
AVA, cm2, median (IQR) 0.8 (0.6–0.9) 0.7 (0.6–0.9) 0.8 (0.6–0.9) 0.19
AVPG, mm Hg, mean (SD) 76 (27.1) 75.5 (25.6) 77.4 (29.1) 0.68
AVMG, mm Hg, median (IQR) 46 (36–56) 46 (36–55) 46.5 (36–57) 0.72
EF, %, median (IQR) 60 (50–65) 60 (50–65) 60 (52.5–65) 0.44
ARc 34 (24.6) 22 (28.2) 12 (20) 0.004
MRc 42 (30.9) 24 (31.6) 17 (29.3) 0.57
TRc 28 (20.7) 20 (25.6) 8 (14) 0.32
Data are presented as number (percentage) unless otherwise indicated.
a Creatinine >200 mmol/l
b Moderate and severe frailty according to the Clinical Frailty Scale
c Moderate and severe
Abbreviations: AR, aortic regurgitation; AVA, aortic valve area; AVMG, aortic valve mean gradient; AVPG, aortic valve peak gradient; BMI, body mass index; CABG, coronary 
artery bypass grafting; COPD, chronic obstructive pulmonary disease; EF, ejection fraction; EuroSCORE, European System for Cardiac Operative Risk Evaluation; 
IQR, interquartile range; LV, left ventricular; MR, mitral regurgitation; NYHA, New York Heart Association; PAD, peripheral artery disease; PCI, percutaneous coronary 
intervention; PH, pulmonary hypertension; RV, right ventricular; STS, Society of Thoracic Surgeons; TIA, transient ischemic accident attack; TR, tricuspid regurgitation
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Postprocedural hemostasis was achieved either 
surgically or percutaneously with the use of double 
Perclose ProGlide (Abbott Vascular, Santa Clara, Cal‑
ifornia, United States) and single 8‑French Angio‑
‑Seal (Terumo Interventional Systems, Somerset, 
New Jersey, United States) devices for primary 
180 bpm. When high ‑grade AVB occurred dur‑
ing the procedure, temporary stimulation was 
provided through the LV guidewire, while ve‑
nous access for RV pacing was obtained. Fur‑
ther stages of transfemoral TAVI procedures 
were carried out typically.
TABLE 2 Procedural data by the pacing method used
Characteristic All study patients (n = 143) Direct LV wire pacing (n = 82) RV lead pacing (n = 61) P value
Complete percutaneous access 82 (57.3) 47 (57.3) 35 (43.1) 0.18
Valve type
Self ‑expandablea 114 (79.7) 73 (89) 41 (67.2) <0.001
Balloon ‑expandableb 26 (18.2) 9 (11) 17 (27.9) <0.001
Mechanically expandablec 3 (2.1) 0 3 (4.9) 0.88
Procedure
Procedure duration, min, median (IQR) 80 (70–95) 80 (70–90) 85 (70–95) 0.02
Radiation dose, mGy, median (IQR) 507 (324–920) 575.5 (356.8–974) 437 (265–664) 0.02
Contrast agent, ml, median (IQR) 150 (100–179) 150 (122.5–186) 120 (100–150) 0.007
Predilatation 112 (78.3) 71 (86.6) 41 (67.2) 0.006
Postdilatation 96 (67.1) 59 (72) 37 (60.7) 0.16
Complications
Valve displacement 2 (1.4) 1 (1.2) 1 (1.6) 0.5
Second valve, bailout 4 (2.8) 1 (1.2) 3 (4.9) 0.1
AVB requiring pacing 7 (4.9) 3 (3.7) 4 (6.6) 0.01
Tamponade 2(1.4) 0 2 (3.3) 0.34
Cardiogenic shock 4 (2.8) 1 (1.2) 3 (4.9) 0.32
Conversion to surgery 0 0 0 NA
Data are presented as number (percentage) unless otherwise indicated.
a  Medtronic Evolut R, Boston Scientific ACURATE Neo
b Edwards Sapien 3
c  Boston Scientific LOTUS
Abbreviations: AVB, atrioventricular block; NA, not applicable; others, see TABLE 1
TABLE 3 Procedural data by the valve type used
Characteristic Self ‑expandablea (n = 114) Balloon ‑expandableb (n = 26) Mechanically expandablec (n = 3) P value
Pacing method, n (%)
Direct LV wire pacing 73 (64) 9 (34.6) 0 <0.001
RV lead pacing 41 (36) 17 (65.4) 3 (100) <0.001
Procedural data, median (IQR)
Procedure duration, min 80 (70–95) 85 (70–90) 70 (67.5–71.3) 0.2
Radiation dose, mGy 507 (298–844.5) 639 (419–1024) 381.5 (341.8–445.5) 0.25
Contrast agent, ml 150 (120–170) 130 (100–196.5) 135 (115–162.5) 0.98
a Medtronic Evolut R, Boston Scientific ACURATE Neo
b Edwards Sapien 3
c  Boston Scientific LOTUS
Abbreviations: see TABLE 1
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Distribution fitting, 2‑way and multiway tables, 
the Wilcoxon test, the χ2 test, the Mann–Whitney 
test, the independent t test, and the Spearman R 
statistical analyses were performed using the Sta‑
tistica 13.3 software (Tibco Software, Inc., Palo 
Alto, California, United States). A P value less 
than 0.05 was considered significant.
RESULTS From January 2017 to Decem‑
ber 2018, 143 consecutive patients underwent 
a transfemoral TAVI procedure in our center. 
arteriotomy. The secondary vascular access site was 
closed with a 6‑French Angio ‑Seal (Terumo Inter‑
ventional Systems) vascular plug.
Statistical analysis Standard descriptive sta‑
tistics was applied to baseline, procedural, and 
postprocedural characteristics. Continuous vari‑
ables with normal distribution were presented 
as mean (SD), nonnormally distributed variables 
were reported as median (interquartile range), 
whereas ranges and categorical variables were 
presented as numbers (percentages).
TABLE 4 Hospital stay of the study patients
All study patients (n = 143) Direct LV wire pacing (n = 82) RV lead pacing (n = 61) P value
NYHA class
I 27 (20.6) 12 (15.2) 15 (28.9) 0.045
II 100 (76.3) 66 (83.5) 34 (65.4)
III 4 (3) 1 (1.3) 3 (5.8)
IV 0 0 0
Hospital stay characteristics
Maximum creatinine level, mmol/l, 
median (IQR)
102 (82–127) 102.5 (85–126) 100 (79–127) 0.54
Lowest hemoglobin level, g/dl, 
median (IQR)
10 (9–11.1) 10 (9.2–11.4) 10 (8.9–10.9) 0.7
Vascular complications Any 12 (8.4) 5 (6.1) 7 (11.5) 0.31
Arterial 9 (6.3) 5 (6.1) 4 (6.6) 0.39
Venous 3 (2.1) 0 3 (4.9) 0.08
VARC‑2 minor 9 (6.3) 5 (6.1) 4 (6.6) 0.39
VARC‑2 major 3 (2.1) 0 3 (4.9) 0.08
Blood transfusion 11 (7.7) 2 (2.4) 9 (14.8) 0.02
Hospitalization, d, median (IQR) 6 (4.8–7) 5 (4–7) 6 (5–7.8) 0.31
Permanent pacemaker 14 (9.8) 4 (4.9) 10 (16.4) 0.003
Stroke 4 (2.8) 3 (3.7) 1 (1.6) 0.30
In ‑hospital death 2 (1.4) 1 (1.2) 1 (1.6) 0.85
MACEa 11 (7.7) 4 (4.9) 7 (11.5) 0.13
Echocardiography
AVPG, mm Hg, median (IQR) 15 (10–19) 14 (10–18) 15 (10–22.5) 0.12
AVMG, mm Hg, median (IQR) 9 (6–12) 9 (6–11) 10 (7–14) 0.58
EF, %, median (IQR) 60 (50–60) 59 (49–59) 62 (53–65) 0.04
PVLb 20 (14) 11(13.4) 9 (14.8) 0.81
MRc 25 (17.5) 17(20.7) 8 (13.1) 0.37
TRc 24 (16.8) 16(19.5) 8 (13.1) 0.49
Pericardial effusion 20 (14) 16 (19.5) 4 (6.6) 0.03
Data are presented as number (percentage) unless otherwise indicated.
a Stroke, death, venous puncture–related complications, cardiac tamponade
b Moderate, no severe perivalvular leaks
c Moderate and severe
Abbreviations: MACE, major adverse cardiovascular event; PVL, perivalvular leak; VARC‑2, Valve Academic Research Consortium 2; others, see TABLE 1
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of unselected patients undergoing both self‑ and 
balloon ‑expandable transfemoral TAVI procedures.
Right ventricular lead pacing is time‑
‑consuming and may be associated with vascu‑
lar complications, ie, bleeding, hematoma, infec‑
tion, thrombosis, arteriovenous fistula, and peri‑
cardial complications ranging from trivial effu‑
sion to cardiac tamponade. Lack of stability and 
lead disengagement are common problems that 
can potentially lead to dramatic complications.
Traditionally, many institutions leave the RV 
pacing wire in situ for 24 hours, especially in pa‑
tients receiving self ‑expandable valves, owing 
to the risk of late complete AVB. This approach 
is no longer required because of decreased oc‑
currence of AVB associated with the new gen‑
eration of valves, improved implantation tech‑
nique, and frequent late (after over 24 hours) 
AVB development. In most centers, the RV pac‑
ing lead is instantly removed upon the end of 
the TAVI procedure. This technical progress 
and gained experience have enabled us to im‑
plement the new direct LV stimulation tech‑
nique in our center.
Meier and Rutishauser12 first reported on 
the use of guidewires for pacing during cardi‑
ac procedures in 1985. They described a LV pac‑
ing technique with the 0.035‑inch wire used in 
a series of 10 patients undergoing diagnostic 
cardiac catheterization. This method was used 
in several cases of aortic valvuloplasty in both 
adult and pediatric patients and subsequent‑
ly neglected.7,13 Since then, the use of TAVI has 
rapidly expanded, procedures have been grad‑
ually simplified and become safer and less inva‑
sive. Meanwhile, this strategy has been report‑
ed only in a few publications.6,8-11,14 -16
A randomized EASY TAVI (Direct Left Ventric‑
ular Rapid Pacing via the Valve Delivery Guide‑
‑wire in TAVR) trial comparing LV guidewire pac‑
ing with conventional RV lead pacing has been re‑
cently published.17 The main findings of the trial 
were that the use of the LV guidewire for rapid 
ventricular pacing during TAVI with a balloon‑
‑expandable valve was safe and effective. It was 
associated with reduced procedure duration, flu‑
oroscopy time, and cost compared with the use 
of conventional RV lead pacing. The EASY TAVI 
trial included only a highly selected group of pa‑
tients undergoing balloon ‑expandable TAVI pro‑
cedures. On the contrary, our study confirmed 
the suitability of LV guidewire pacing in a broad‑
er range of all ‑comers with the use of both bal‑
loon‑ and self ‑expandable valves.
According to our observations, direct LV wire 
pacing simplifies the procedure by eliminating 
the need for a temporary pacing wire. This meth‑
od provides very constant and stable stimulation 
in most patients (97.6%) and is reliable for use 
with balloon ‑expandable valves where consistent 
pacing is crucial. The technique reduces proce‑
dural time by 5% despite the more frequent use 
The baseline characteristics of the 2 study groups 
did not vary significantly (TABLE 1).
Direct LV wire pacing was used in 82 patients 
and successfully implemented (systolic pres‑
sure drop below 60 mm Hg for more than 30 s 
without loss of capture) in 80 of them. There‑
fore, the efficacy of the new pacing technique 
was 97.6%. The loss of capture occurred in 2 pa‑
tients during stimulation control and predilata‑
tion, yet it had no clinical consequences.
Self ‑expandable Medtronic Evolut R (78 pa‑
tients) and Boston Scientific ACURATE Neo (36 pa‑
tients) valves were mainly used in the study group. 
The most common pacing method was direct LV 
wire pacing, whereas RV lead pacing was used more 
frequently with balloon ‑expandable valves (TABLE 2).
The procedural time was shorter for LV wire 
pacing, but direct LV wire pacing required 
a higher radiation dose and a greater amount 
of a contrast agent (TABLE 2). These parameters 
did not differ when analyzed by the type of 
the implanted valve (TABLE 3). Left ventricular 
wire pacing was approximately EUR 130 (USD 
145) cheaper than RV lead pacing considering 
costs of an intravenous sheath, a pacing elec‑
trode, and the Angio ‑Seal device.
No cardiac tamponade was observed in the di‑
rect LV wire pacing group, but it occurred in 2 
patients in the RV lead pacing group, although 
no statistical significance was achieved. Both 
cases of tamponade were linked to temporary 
RV pacing. One case of valve dislodgement oc‑
curred in each study group and required implan‑
tation of a second valve. None of the patients re‑
quired conversion to surgery. Procedural details 
are presented in TABLES 2 and 3.
Two patients died during hospital stay (TABLE 4), 
one in each of the study groups. Septic shock was 
the direct cause of death in both cases. The fre‑
quency of vascular complications and stroke 
rates were similar in both groups. Three patients 
in the RV lead pacing group had venous punc‑
ture–related complications (hematomas), con‑
firmed by ultrasound, but no statistical signifi‑
cance was found. Patients in the RV lead pacing 
group required blood transfusion more frequent‑
ly than those in the direct LV wire pacing group.
Major adverse cardiovascular events (a com‑
bined endpoint including stroke, death, venous 
puncture–related complications, and cardiac tam‑
ponade) were more frequent in the RV lead pacing 
group, but no statistical significance was found.
Patients paced with the guidewire had low‑
er ejection fraction at discharge, more frequent 
clinically nonsignificant pericardial effusion, 
and more pronounced symptoms of heart fail‑
ure at discharge.
DISCUSSION This study for the first time com‑
pared the use of direct LV wire pacing and the con‑
ventional method (RV lead pacing) in a population 





































































of self ‑expandable valves; thus, it has a poten‑
tial to increase implantation tolerance.
The reported technique is safe and seems to be 
noninferior to the traditional stimulation meth‑
od, even though it requires a greater amount of 
a contrast agent and is associated with a higher 
accumulated radiation dose along with poten‑
tial mild LV muscle injury (lower ejection frac‑
tion at discharge, more frequent pericardial ef‑
fusion, more pronounced symptoms of heart fail‑
ure at discharge). We associate these debatable 
adverse events with the necessity of more fre‑
quent predilatation in the direct LV pacing group 
rather than the pacing method itself.
A relatively low rate of arterial access–relat‑
ed vascular complications, compared with the 
results of previous domestic publications, was 
achieved with the systematic use of a combi‑
nation of 2 suture ‑based and 1 collagen foot‑
print–based closing devices.18-20 According to lo‑
cal practice, angiographic guidance was used for 
the precise localization of the optimal common 
femoral artery puncture site. Surgical cutdown 
was chosen when a fully percutaneous approach 
was assumed to be unpredictable based on com‑
puted tomography characteristics of the femo‑
ral artery.21
Study limitations Undoubtedly, our study was 
limited by some factors. We reported only a non‑
randomized series of patients, a relatively small 
population from a single TAVI center. Further‑
more, the study design was retrospective, and 
the operator could have biased the decision on 
the use of particular pacing techniques. More‑
over, in 2017 and 2018, balloon ‑tipped RV pac‑
ing electrodes, whose use is currently the gold 
standard, were unavailable in our TAVI center.
Conclusions This is the first study comparing 
the direct LV wire pacing technique and the con‑
ventional RV lead pacing method in a popula‑
tion of unselected patients undergoing TAVI 
procedures.
Direct LV wire pacing during TAVI seems 
to be simple, reproducible, and safe. This new 
technique provides reliable, sustained stimu‑
lation characterized by a low complication rate 
and showing a potential reduction in procedur‑
al time and cost.
Further studies, preferably a larger random‑
ized trial, are necessary to confirm the benefits 
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